Good morning, everyone, and how are you today? We are doing just fine, thank you, despite a drop of snow that has descended on the frosty Pharmalot campus. No matter. We have managed to dispense with the white stuff, fire up the coffee kettle, and even assemble the below list of items of interest. This is why a few cups of stimulation are in order. Our choice today is hot-buttered rum, for those who track this sort of thing or wish to experiment. In any event, have a lovely day, stay warm and, as always, do keep in touch.

In the early days of OxyContin, Dr. Richard Sackler, a member of the Sackler family who founded and controls Purdue Pharma, learned about concerns the potent opioid could lead to abuse in chronic pain patients, and he then proposed executives aggressively push back, according to newly unsealed documents obtained by STAT. In emails, he said executives should consider giving a “convincing presentation” that controlled-release products like OxyContin are “less prone to addiction potential, abuse or diversion” than other opioid pain pills.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy